{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:02Z","timestamp":1791110882292,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Steve Prescott Foundation Charity"},{"name":"The Christie Charity"},{"name":"Manchester Cancer Research Centre and The University of Manchester research bursary"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Genetic biomarkers guide systemic anti-cancer treatment (SACT) in metastatic colorectal cancer. It has been suggested they have a role in selecting patients with colorectal peritoneal metastases (CRPM) for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). This study aims to quantify the effect of mutation status on overall survival (OS), adjusting for confounders such as pre-operative systemic anticancer treatment (SACT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Retrospective analysis of patients undergoing CRS\/HIPEC for CRPM at a national peritoneal tumour centre (2004\u20132017) was performed. Demographics, treatment history and operative data were extracted. Known biomarker gene mutation status was noted including: <jats:italic>KRAS<\/jats:italic>, <jats:italic>NRAS<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic> and <jats:italic>MMR<\/jats:italic>. Cox regression analysis and Kaplan\u2013Meier curves were used to determine overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred ninety-five patients were included. Median follow-up time was 34.7 months (range 5.4\u2013184.9 months) and median OS was 38.7 months (95% CI 32.4\u201344.9 months). Biomarker status was as follows: <jats:italic>KRAS<\/jats:italic> (<jats:italic>n<\/jats:italic> = 114), <jats:italic>NRAS<\/jats:italic> (<jats:italic>n<\/jats:italic> = 85), <jats:italic>BRAF<\/jats:italic> (<jats:italic>n<\/jats:italic> = 44), <jats:italic>PIK3CA<\/jats:italic> (<jats:italic>n<\/jats:italic> = 15) and <jats:italic>MMR<\/jats:italic> (<jats:italic>n<\/jats:italic> = 21). Mutation rates were 45.6%, 3.5%, 13.6%, 13.3% and 14.3%, respectively. Seventy-four per cent underwent complete cytoreduction (CC = 0), 81% received SACT pre-CRS\/HIPEC and 65% post-CRS\/HIPEC. RAS (<jats:italic>p<\/jats:italic> = 0.21) or <jats:italic>BRAF<\/jats:italic> (<jats:italic>p<\/jats:italic> = 0.109) mutation status did not predict OS. Nodal involvement, extramural vascular invasion, Peritoneal Cancer Index (PCI) score, CC score, SACT post-HIPEC and <jats:italic>NRAS<\/jats:italic> mutation were significant negative predictors of OS in univariate analysis (<jats:italic>p<\/jats:italic> &lt; 0.05). Multivariate Cox regression confirmed CC-score &gt; 1 (HR: 7.599, 95% CI 3.402\u201316.974, <jats:italic>p<\/jats:italic> &lt; 0.0001) as a negative predictor of OS. RAS mutation status did not affect outcome (HR: 1.682, 95% CI 0.995\u20132.843, <jats:italic>p<\/jats:italic> = 0.052).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RAS mutation status should not in isolation be used to select patients for CRS\/HIPEC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12704-9","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T19:04:15Z","timestamp":1668798255000},"page":"792-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases"],"prefix":"10.1245","volume":"30","author":[{"given":"Dilraj","family":"Bhullar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"2","key":"12704_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jclinpath-2018-205471","volume":"72","author":"O Saeed","year":"2019","unstructured":"Saeed O, Lopez-Beltran A, Fisher KW, et al. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol. 2019;72(2):135\u20139. https:\/\/doi.org\/10.1136\/jclinpath-2018-205471.","journal-title":"J Clin Pathol."},{"issue":"11","key":"12704_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351. https:\/\/doi.org\/10.1038\/nrd4389.","journal-title":"Nat Rev Drug Discov."},{"issue":"6120","key":"12704_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/327293a0","volume":"327","author":"JL Bos","year":"1987","unstructured":"Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293\u20137. https:\/\/doi.org\/10.1038\/327293a0.","journal-title":"Nature"},{"issue":"9","key":"12704_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM198809013190901","volume":"319","author":"B Vogelstein","year":"1988","unstructured":"Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525\u201332. https:\/\/doi.org\/10.1056\/NEJM198809013190901.","journal-title":"N Engl J Med."},{"issue":"3","key":"12704_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):263\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.37.1039.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"12","key":"12704_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"issue":"12","key":"12704_CR7","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.ejso.2019.07.008","volume":"45","author":"A Larentzakis","year":"2019","unstructured":"Larentzakis A, O\u2019Dwyer ST, Becker J, et al. Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). Eur J Surg Oncol. 2019;45(12):2310\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2019.07.008.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"12704_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"5","key":"12704_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, et al. Mutations of RAS\/RAF Proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845\u201353. https:\/\/doi.org\/10.1097\/SLA.0000000000002899.","journal-title":"Ann Surg."},{"key":"12704_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jss.2019.02.050","volume":"240","author":"Z Morgan","year":"2019","unstructured":"Morgan Z, Chow BE, Strong EA, et al. RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res. 2019;240:130\u20135. https:\/\/doi.org\/10.1016\/j.jss.2019.02.050.","journal-title":"J Surg Res."},{"issue":"8","key":"12704_CR11","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1245\/s10434-019-07378-9","volume":"26","author":"A Arjona-Sanchez","year":"2019","unstructured":"Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;26(8):2595\u2013604. https:\/\/doi.org\/10.1245\/s10434-019-07378-9.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"12704_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","volume":"27","author":"W Graf","year":"2020","unstructured":"Graf W, Cashin PH, Ghanipour L, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27(1):293\u2013300. https:\/\/doi.org\/10.1245\/s10434-019-07452-2.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"12704_CR13","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1245\/s10434-020-09161-7","volume":"28","author":"D Baratti","year":"2021","unstructured":"Baratti D, Kusamura S, Niger M, et al. Prognostic impact of primary side and RAS\/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. Ann Surg Oncol. 2021;28(6):3332\u201342. https:\/\/doi.org\/10.1245\/s10434-020-09161-7.","journal-title":"Ann Surg Oncol."},{"key":"12704_CR14","doi-asserted-by":"crossref","unstructured":"Aziz O, Jaradat I, Chakrabarty B, et al. Predicting survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendix adenocarcinoma. Dis Colon Rectum. 2018;61(7).","DOI":"10.1097\/DCR.0000000000001076"},{"issue":"2","key":"12704_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/cancers12020319","volume":"12","author":"E Koncina","year":"2020","unstructured":"Koncina E, Haan S, Rauh S, Letellier E. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers. 2020;12(2):319. https:\/\/doi.org\/10.3390\/cancers12020319.","journal-title":"Cancers."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12704-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T14:08:39Z","timestamp":1672668519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12704-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["12704"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12704-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}